Partner Jeffrey Fessler Represents ContraVir Pharmaceuticals, Inc. on $7.0 Million Public Offering of Common Stock and Warrants
Press Release – New York, NY – April 5, 2016 – Securities and corporate law firm Sichenzia Ross Friedman Ference LLP is pleased to announce that the Firm has represented ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV), a biopharmaceutical company focused on
the development and commercialization of targeted antiviral therapies, on an underwritten public offering of 4,929,578 shares of the Company’s common stock and warrants to purchase up to 2,464,789 shares of common stock at a combined public offering price of $1.42. ContraVir raised $7,000,000 in gross proceeds. Laidlaw & Company (UK) Ltd. was the sole book-running manager for the offering.
The Sichenzia Ross Friedman Ference LLP team was led by Partners Jeffrey J. Fessler and Stephen A. Cohen.
Visit SRF's LinkedIn page
Latest posts by Sichenzia Ross Ference LLP (see all)
- Attorneys Selected for Inclusion on 2019 Super Lawyers Lists - October 16, 2019
- Sichenzia Ross Ference LLP to Join Client Relmada Therapeutics, Inc. at Nasdaq Opening Bell Ringing - October 15, 2019
- Sichenzia Ross Ference LLP Congratulates Relmada Therapeutics, Inc., on NASDAQ Uplisting - October 10, 2019